CONTENTS:
- Let actual markets help assess the worth of optional very-low-nicotine cigarettes before deciding on mandatory regulations [Editorial]. Kozlowski L.T., p. 3-5.
- Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game [Editorial]. Benowitz N.L., Donny E.C., Hatsukami D.K., p. 6-7.
- A framework for evaluating the public health impact of e-cigarettes and other vaporized nicotine products [Addiction debate]. Levy D.T., Cummings K.M., Villanti A.C., Niaura R., Abrams D.B., Fong G.T., et al., p. 8-17.
- The potential impact of vaporized nicotine products on vulnerable subpopulations. Gartner C., p. 18-19.
- Is public health regulation the biggest factor influencing the use and uptake of vaporized nicotine products? Freeman B., p. 19-21.
- A gateway to more productive research on e-cigarettes? Commentary on a comprehensive framework for evaluating public health impact. Brown J., p. 21-22.
- The need for a comprehensive framework. Levy D.T., Fong G.T., Cummings K.M., Borland R., Abrams D.B., Villanti A.C., et al., p. 22-24.
- Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill [Addiction debate]. Reuter P., Pardo B., p. 25-31.
- Which policy for new psychoactive drugs? Uchtenhagen A., p. 32-33.
- The unbearable lightness of simplicity. Krajewski K., p. 33-34.
- Recent developments with the New Zealand regulated market approach to 'low-risk' psychoactive products. Wilkins C., Rychert M., p. 34-36.
- New psychoactive substances: driving greater complexity into the drug problem. Evans-Brown M., Sedefov R., p. 36-38.
- A chorus of pessimism surrounding the new psychoactive substances problem. Pardo B., Reuter P., p. 38-39.
- Social cognition in alcohol use disorder: a meta-analysis. Bora E., Zorlu N., p. 40-48.
- Commentary on Bora & Zorlu (2017): Social cognition deficits in addiction - an attachment problem? Kornreich C., p. 49-50.
- Steep delay discounting and addictive behavior: a meta-analysis of continuous associations. Amlung M., Vedelago L., Acker J., Balodis I., MacKillop J., p. 51-62.
- The party effect: prediction of future alcohol use based on exposure to specific alcohol advertising content. Morgenstern M., Li Z., Li Z., Sargent J.D., p. 63-70.
- Commentary on Morgenstern et al. (2017): Party-themed advertisements and initiation of alcohol consumption. Morojele N.K., Parry C.D.H., p. 71-72.
- Effects of sex and alcohol use on antiretroviral therapy outcomes in Botswana: a cohort study. Gross R., Bellamy S.L., Ratshaa B., Han X., Steenhoff A.P., Mosepele M., et al., p. 73-81.
- High-intensity drinking by underage young adults in the United States. Patrick M.E., Terry-McElrath Y.M., p. 82-93.
- Is online information on ecstasy tablet content safe? Vrolijk R.Q., Brunt T.M., Vreeker A., Niesink R.J.M., p. 94-100.
- Commentary on Vrolijk et al. (2017): The paradox of the quality control problem. Barratt M.J., Ritter A., p. 101-102.
- Prescription opioid poisoning across urban and rural areas: identifying vulnerable groups and geographic areas. Cerdá M., Gaidus A., Keyes K.M., Ponicki W., Martins S., Galea S., et al., p. 103-112.
- The genetic basis of the comorbidity between cannabis use and major depression. Hodgson K., Almasy L., Knowles E.E.M., Kent J.W., Curran J.E., Dyer T.D., et al., p. 113-123.
- Effects of accountable care and payment reform on substance use disorder treatment: evidence from the initial 3 years of the alternative quality contract. Stuart E.A., Barry C.L., Donohue J.M., Greenfield S.F., Duckworth K., Song Z., et al., p. 124-133.
- The effect of prenatal smoking exposure on daily smoking among teenage offspring. Niemelä S., Räisänen A., Koskela J., Taanila A., Miettunen J., Ramsay H., et al., p. 134-143.
- Commentary on Niemelä et al. (2017): Maternal smoking during pregnancy - an independent risk factor of postnatal health disorders. Berlin I., p. 144-145.
- Motivational, reduction and usual care interventions for smokers who are not ready to quit: a randomized controlled trial. Klemperer E.M., Hughes J.R., Solomon L.J., Callas P.W., Fingar J.R., p. 146-155.
- Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial. Hatsukami D.K., Luo X., Dick L., Kangkum M., Allen S.S., Murphy S.E., et al., p. 156-167.
- Development of a proto-typology of opiate overdose onset. Neale J., Bradford J., Strang J., p. 168-175.
- Lee Robins' studies of heroin use among US Vietnam veterans. Hall W., Weier M., p. 176-180.
- Thirty-one psychoactive plants exempted from New Zealand's Psychoactive Substances Act 2013. Rychert M., Wilkins C., p. 181-182.
- How can we investigate the role of topiramate in the treatment of cocaine use disorder more thoroughly? Klimas J., Wood E., Werb D., p. 182-183.
- Prolonged mental health effects of ethylphenidate beyond cessation of use. Robertson R., p. 183-184.